Advances in antiretroviral therapy

Susan Olender; Timothy J. Wilkin; Barbara S. Taylor; Scott M. Hammer

Advances in antiretroviral therapy

Susan Olender, Timothy J. Wilkin, Barbara S. Taylor, Scott M. Hammer

Research output: Contribution to journal › Article › peer-review

Abstract

The 19th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted new information and provided in-depth discussion on advances in antiretroviral therapy (ART). Data regarding investigational drugs, including integrase strand transfer inhibitors (InSTIs) and zinc-finger nucleases disrupting CC chemokine receptor 5 (CCR5), were presented. Treatment trials in treatment-naive and treatment-experienced patients added to the knowledge base of which antiretroviral agents to initiate and when. Data from trials and observational cohorts suggested that, for patients on successful ART in resource-rich settings, mortality from non-HIV-related diseases may surpass that from HIV-related diseases, and overall lifespan may be nearing that of people without HIV infection. In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented.

Original language	English (US)
Pages (from-to)	61-86
Number of pages	26
Journal	Topics in Antiviral Medicine
Volume	20
Issue number	2
State	Published - Jun 2012

ASJC Scopus subject areas

General Medicine

Cite this

@article{580313ebae174c2fbdd6b31a480fac99,

title = "Advances in antiretroviral therapy",

abstract = "The 19th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted new information and provided in-depth discussion on advances in antiretroviral therapy (ART). Data regarding investigational drugs, including integrase strand transfer inhibitors (InSTIs) and zinc-finger nucleases disrupting CC chemokine receptor 5 (CCR5), were presented. Treatment trials in treatment-naive and treatment-experienced patients added to the knowledge base of which antiretroviral agents to initiate and when. Data from trials and observational cohorts suggested that, for patients on successful ART in resource-rich settings, mortality from non-HIV-related diseases may surpass that from HIV-related diseases, and overall lifespan may be nearing that of people without HIV infection. In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented.",

author = "Susan Olender and Wilkin, {Timothy J.} and Taylor, {Barbara S.} and Hammer, {Scott M.}",

year = "2012",

month = jun,

language = "English (US)",

volume = "20",

pages = "61--86",

journal = "Topics in Antiviral Medicine",

issn = "2161-5861",

publisher = "International Antiviral Society",

number = "2",

}

TY - JOUR

T1 - Advances in antiretroviral therapy

AU - Olender, Susan

AU - Wilkin, Timothy J.

AU - Taylor, Barbara S.

AU - Hammer, Scott M.

PY - 2012/6

Y1 - 2012/6

N2 - The 19th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted new information and provided in-depth discussion on advances in antiretroviral therapy (ART). Data regarding investigational drugs, including integrase strand transfer inhibitors (InSTIs) and zinc-finger nucleases disrupting CC chemokine receptor 5 (CCR5), were presented. Treatment trials in treatment-naive and treatment-experienced patients added to the knowledge base of which antiretroviral agents to initiate and when. Data from trials and observational cohorts suggested that, for patients on successful ART in resource-rich settings, mortality from non-HIV-related diseases may surpass that from HIV-related diseases, and overall lifespan may be nearing that of people without HIV infection. In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented.

AB - The 19th Conference on Retroviruses and Opportunistic Infections (CROI) highlighted new information and provided in-depth discussion on advances in antiretroviral therapy (ART). Data regarding investigational drugs, including integrase strand transfer inhibitors (InSTIs) and zinc-finger nucleases disrupting CC chemokine receptor 5 (CCR5), were presented. Treatment trials in treatment-naive and treatment-experienced patients added to the knowledge base of which antiretroviral agents to initiate and when. Data from trials and observational cohorts suggested that, for patients on successful ART in resource-rich settings, mortality from non-HIV-related diseases may surpass that from HIV-related diseases, and overall lifespan may be nearing that of people without HIV infection. In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented.

UR - http://www.scopus.com/inward/record.url?scp=84867847192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867847192&partnerID=8YFLogxK

M3 - Article

C2 - 22710908

AN - SCOPUS:84867847192

SN - 2161-5861

VL - 20

SP - 61

EP - 86

JO - Topics in Antiviral Medicine

JF - Topics in Antiviral Medicine

IS - 2

ER -

Advances in antiretroviral therapy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this